The FDA has approved Zydus Pharmaceuticals USA Inc.’s intravenous version of lacosamide (ANDA209465), expanding the generic market and increasing competition in the IV anti-seizure segment. This approval is expected to provide healthcare providers with a cost-effective alternative while potentially driving down prices for intravenous lacosamide therapy.